Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Exclusion Criteria

• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period;
• •Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within three months prior to the first vaccine dose.
• •Planned administration/ administration of a vaccine not foreseen by the study protocol within one month before the first study vaccination or scheduled within 30 days after study vaccination;
• •Previous vaccination against HZ;
• •Previous vaccination against varicella;
• •History of HZ;
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine;
• •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy;
• •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first injection of study vaccine or planned administration during the study period;
• •Acute disease at the time of enrolment.
• •Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study;
• •History of or current drug and/or alcohol abuse;
• •Pregnant or lactating female;
• •Female planning to become pregnant or planning to discontinue contraceptive precautions if of childbearing potential.